[{"indications": "Indications\u00a0invasive aspergillosis (\n(From Treatment of fungal infections: British National Formulary)\nTreatment of fungal infections); invasive\r\ncandidiasis (\n(From Treatment of fungal infections: British National Formulary)\nTreatment of fungal infections); empirical treatment of systemic fungal infections in patients\r\nwith neutropenia", "name": "CASPOFUNGIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.2 Antifungal drugs", "5.2.4 Echinocandin antifungals"], "cautions": "Cautions\u00a0interactions: Appendix 1 (caspofungin)", "side-effects": "Side-effects\u00a0nausea, diarrhoea, vomiting; dyspnoea; headache;\r\nhypokalaemia; arthralgia; rash, pruritus, sweating, injection-site\r\nreactions; less commonly abdominal pain, dyspepsia,\r\ndry mouth, dysphagia, taste disturbances, anorexia, constipation,\r\nflatulence, cholestasis, hepatic dysfunction, ascites, palpitation,\r\narrhythmia, chest pain, heart failure, thrombophlebitis, flushing,\r\nhypotension, hypertension, bronchospasm, cough, dizziness, fatigue,\r\nparaesthesia, hypoaesthesia, sleep disturbances, tremor, anxiety,\r\ndisorientation, hyperglycaemia, renal failure, hypomagnesaemia, hypocalcaemia,\r\nmetabolic acidosis, anaemia, thrombocytopenia, leucopenia, myalgia,\r\nmuscular weakness, blurred vision, and erythema multiforme; also reported,\r\nadult respiratory distress syndrome and anaphylaxis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/119732.htm", "doses": ["By intravenous infusion, 70\u00a0mg on first\r\nday then 50\u00a0mg once daily (70\u00a0mg once daily if body-weight over 80\u00a0kg); child under 18 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless essential\u2014toxicity\r\nin animal studies"}]